Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis (ATTR-CM), allowing it to compete head-to-head with rival therapies from ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment can ...

In a review published in Therapeutics and Clinical Risk Management, researchers outlined the current understanding of the transthyretin amyloidosis (ATTR) disease process, diagnostic and surveillance ...

CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to ...

Please provide your email address to receive an email when new articles are posted on . Vutrisiran lowered risk for death and recurrent CV events vs. placebo in patients with ATTR-CM. The results were ...

Transthyretin amyloidosis (ATTR) is not one disease, but a cluster of related conditions. At their core, they stem from a disorder that develops when normal proteins produced by the liver suddenly ...

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...

Scoring tools validated to identify people at high risk of having transthyretin amyloid cardiomyopathy (ATTR-CM) still leave room for improvement in diverse populations. The ATTR-CM score and the ...

Acoramidis (Attruby; BridgeBio), a drug that stabilizes transthyretin and has demonstrated benefit on cardiovascular outcomes, has been approved by the US Food and Drug Administration for the ...

All forms of amyloidosis are caused by the abnormal folding of proteins in our body’s cells. In the case of wild-type ATTR amyloidosis, normal proteins accumulate but are not cleared from organs, ...